M6A Methylation Regulators METTL3 and ALKBH5 are Risk Factors for EGFR-Mutant NSCLC

Abstract excerpt

IntroductionNon-small cell lung cancer (NSCLC), which accounts for >85% of all lung cancers, is the most common solid malignant tumor, with high morbidity and mortality worldwide. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment is widely used clinically because the epidermal growth factor receptor (EGFR) is the main driver gene of lung cancer; however, the development of drug...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related molecular mechanisms research
• Share to Lung Cancer Treatments and Mutations
• Share to RNA modifications and cancer